PTAB Invalidates Claims for Section 112 Failures

Jan 3, 2017

Reading Time : 1 min

The PTAB found that the claims failed the enablement requirement under § 112. First, Petitioner’s evidence showed that the claimed method was inoperative within the claimed temperature range. Specifically, Petitioner described two tests in which none of the tested devices exhibited the claimed deformation. Second, the PTAB found that undue experimentation would be required to practice the full scope of the claimed invention. The specification provided only one narrow example and failed to discuss how to achieve the desired deformation under the broadly claimed temperature range. Third, the PTAB relied on the testimony of the sole named inventor, who did not believe it was possible to achieve the claimed deformation results as of the effective filing date.

In addition, the PTAB concluded that the ’991 patent lacked a sufficient written description. The PTAB explained that the disclosure of one species was insufficient to support the genus of the claimed temperature range. The PTAB relied on the two tests showing that the disclosed embodiments were inoperative and on the inventor’s testimony to show that he was not in possession of the invention.

Moreover, the PTAB clarified that a determination of failure to satisfy the enablement and written description requirements under § 112 was not inconsistent with a finding of anticipation. When a claim covers several compositions, the claim is anticipated if one of them is in the prior art. Accordingly, the PTAB found the claims invalid as being anticipated by the prior art.

US Endodontics, LLC v. Gold Standard Instruments, LLC, Case PGR2015-00019 (PTAB Dec. 28, 2016). [Goodson (opinion), Cocks and Jung]

Share This Insight

Previous Entries

IP Newsflash

June 5, 2026

The Supreme Court unanimously held that for a complaint of induced infringement, a patent owner must allege that the accused infringer took affirmative, not passive, steps to encourage direct infringement. Thus, where a generic drug has a skinny label, to induce infringement of the carved-out patented use of the drug, the generic company must have taken steps that were designed to cause others to perform the patented use, not just steps that could cause such conduct.

...

Read More

IP Newsflash

May 07, 2026

The Northern District of Illinois granted a summary judgment motion of no invalidity based on indefiniteness because the qualitative terms like “sufficiently slow” and “desired period of time” were definite when viewed in light of the surrounding claim language and specification.

...

Read More

IP Newsflash

April 9, 2026

In the April 1, 2026 edition of the Official Gazette, the U.S. Patent and Trademark Office announced a new procedural framework that permits patent owners to submit a limited, early response to a request for ex parte reexamination.

...

Read More

IP Newsflash

March 12, 2026

The Northern District of Illinois recently dismissed a complaint without prejudice for failing to plausibly allege patent infringement. The court found that the allegations of direct infringement were insufficiently pled where the images of the accused product included in the complaint did not appear to show a particular necessary element of the claims.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.